Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2025)

Amylyx Pharmaceuticals has reported Income from Continuing Operations over the past 5 years, most recently at 111578000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 111578000.0 for Q4 2025, down 57.77% from a year ago — trailing twelve months through Dec 2025 was 158000.0 (down 1228.57% YoY), and the annual figure for FY2025 was 158000.0, down 1228.57%.
  • Income from Continuing Operations for Q4 2025 was 111578000.0 at Amylyx Pharmaceuticals, up from 34386000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for AMLX hit a ceiling of 264211000.0 in Q4 2024 and a floor of 118793000.0 in Q1 2024.
  • Median Income from Continuing Operations over the past 5 years was 25729500.0 (2021), compared with a mean of 1730700.0.
  • Peak annual rise in Income from Continuing Operations hit 2984.78% in 2024, while the deepest fall reached 7652.0% in 2024.
  • Amylyx Pharmaceuticals' Income from Continuing Operations stood at 28317000.0 in 2021, then soared by 650.92% to 156005000.0 in 2022, then tumbled by 94.51% to 8565000.0 in 2023, then surged by 2984.78% to 264211000.0 in 2024, then plummeted by 57.77% to 111578000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 111578000.0 (Q4 2025), 34386000.0 (Q3 2025), and 41443000.0 (Q2 2025) per Business Quant data.